Comprehensive ex vivo and in vivo preclinical evaluation of novel chemo enzymatic decellularized peripheral nerve allografts

Front Bioeng Biotechnol. 2023 Mar 30:11:1162684. doi: 10.3389/fbioe.2023.1162684. eCollection 2023.

Abstract

As a reliable alternative to autografts, decellularized peripheral nerve allografts (DPNAs) should mimic the complex microstructure of native nerves and be immunogenically compatible. Nevertheless, there is a current lack of decellularization methods able to remove peripheral nerve cells without significantly altering the nerve extracellular matrix (ECM). The aims of this study are firstly to characterize ex vivo, in a histological, biochemical, biomechanical and ultrastructural way, three novel chemical-enzymatic decellularization protocols (P1, P2 and P3) in rat sciatic nerves and compared with the Sondell classic decellularization method and then, to select the most promising DPNAs to be tested in vivo. All the DPNAs generated present an efficient removal of the cellular material and myelin, while preserving the laminin and collagen network of the ECM (except P3) and were free from any significant alterations in the biomechanical parameters and biocompatibility properties. Then, P1 and P2 were selected to evaluate their regenerative effectivity and were compared with Sondell and autograft techniques in an in vivo model of sciatic defect with a 10-mm gap, after 15 weeks of follow-up. All study groups showed a partial motor and sensory recovery that were in correlation with the histological, histomorphometrical and ultrastructural analyses of nerve regeneration, being P2 the protocol showing the most similar results to the autograft control group.

Keywords: acellular graft; decellularization; decellularized nerve allograft; peripheral nerve repair; tissue engineering.

Grants and funding

This research study was funded by the Spanish “Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica, Ministerio de Economía y Competitividad (Instituto de Salud Carlos III)”, Grants FIS PI17-0393 and FIS PI20-0318 co-financed by “Fondo Europeo de Desarrollo RegionalERDF-FEDER European Union”; Grant P18-RT-5059 “Plan Andaluz de Investigación, Desarrollo eInnovación (PAIDI 2020), Consejería de Transformación Económica, Industria, Conocimiento yUniversidades, Junta de Andalucía, España”; Grant PI-0086-2020, “Consejería de Salud y Consumo, Junta de Andalucía, España”; Grant A-CTS-498-UGR18 by “Programa Operativo FEDER Andalucía2014–2020, Universidad de Granada, Junta de Andalucía, España”, co-funded by ERDF-FEDER, theEuropean Union; Grant CPP2021-009070 by the “Proyectos de colaboración público-privada, Plan deInvestigación Científica, Técnica y de Innovación 2021-2023, Ministerio de Ciencia e Innovación, Unión Europea (NextGeneration EU), Agencia Estatal de Investigación, España”.